Giving

Department of Oncology

Cumming School of Medicine, University of Calgary 

In partnership with Arnie Charbonneau Cancer Institute

Department of Oncology

Cumming School of Medicine, University of Calgary 

In partnership with Arne Charbonneau Cancer Institute

Watson, Alexander

Medical Oncology

Clinical Assistant Professor

Web Presence:

https://www.ncbi.nlm.nih.gov/myncbi/alexander%20scarth.watson.1/bibliography/public/

Biography

Dr Alexander (Alec) Watson is a medical oncologist at the Arthur J.E. Child Comprehensive Cancer Centre and an Assistant Professor at the University of Calgary. He specializes in the treatment of thoracic malignancies. His research interests centre around early phase clinical trials, investigating toxicities of novel therapeutic agents, and translational collaborations examining predictors of responses to cancer treatments. He received a B.Sc. from the University of Victoria (2010), obtained a D.Phil. in cancer biology and immunology at the University of Oxford (2014). He then completed medical school at the University of British Columbia (2018), residency training in Internal Medicine and Medical Oncology at the University of Calgary (2023) and an advanced fellowship in Thoracic Oncology and Investigational Cancer Therapeutics at the University of Colorado (2025). Outside of the cancer centre, he is a keen endurance athlete and outdoor enthusiast.

Area of Focus

Thoracic Oncology, Clinical Trials

Summary of Research

  1. Richardson NH, Watson AS, Patil T, Camidge DR, Hanna NH, Shields MD. Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review. Clin Lung Cancer. 2025 Dec;26(8):680-684. doi: 10.1016/j.cllc.2025.08.015. Epub 2025 Aug 26. PubMed PMID: 40957783.
  2. Watson AS, Staley AW, Yoder B, Iwamoto SJ, Alami V, Schenk EL, Patil T, Camidge DR, Taormina JM. Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2025 Sep;6(9):100870. doi: 10.1016/j.jtocrr.2025.100870. eCollection 2025 Sep. PubMed PMID: 40800726; PubMed Central PMCID: PMC12341509.
  3. Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19;16(1):7717. doi: 10.1038/s41467-025-63091-0. PubMed PMID: 40830141; PubMed Central PMCID: PMC12365225.
  4. Watson A, Patil T, Schenk E, Camidge D. Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review. Current Problems in Cancer: Case Reports. 2025/03; 17:100348.
  5. Phillips WJ, Watson AS, Camidge DR. The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments. J Thorac Oncol. 2025 May;20(5):589-596. doi: 10.1016/j.jtho.2024.12.003. Epub 2024 Dec 4. PubMed PMID: 39643116.
  6. Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2025 Jan;199:108040. doi: 10.1016/j.lungcan.2024.108040. Epub 2024 Nov 25. PubMed PMID: 39615411; PubMed Central PMCID: PMC11787869.
  7. Watson AS, Krause HB, Elliott A, Farrell A, Liu SV, Ma PC, VanderWalde A, Sledge GW, Spetzler D, Schenk EL, Camidge DR. Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2024 Dec;25(8):712-722.e1. doi: 10.1016/j.cllc.2024.09.001. Epub 2024 Sep 12. PubMed PMID: 39384504.
  8. Watson AS, Goutam S, Stukalin I, Ewanchuk BW, Sander M, Meyers DE, Pabani A, Cheung WY, Heng DYC, Cheng T, Monzon JG, Navani V. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy. JAMA Netw Open. 2022 Dec 1;5(12):e2245596. doi: 10.1001/jamanetworkopen.2022.45596. PubMed PMID: 36480204; PubMed Central PMCID: PMC9856439

Area Of Focus

Thoracic Oncology, Clinical Trials

Summary Of Research

  1. Richardson NH, Watson AS, Patil T, Camidge DR, Hanna NH, Shields MD. Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review. Clin Lung Cancer. 2025 Dec;26(8):680-684. doi: 10.1016/j.cllc.2025.08.015. Epub 2025 Aug 26. PubMed PMID: 40957783.
  2. Watson AS, Staley AW, Yoder B, Iwamoto SJ, Alami V, Schenk EL, Patil T, Camidge DR, Taormina JM. Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2025 Sep;6(9):100870. doi: 10.1016/j.jtocrr.2025.100870. eCollection 2025 Sep. PubMed PMID: 40800726; PubMed Central PMCID: PMC12341509.
  3. Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19;16(1):7717. doi: 10.1038/s41467-025-63091-0. PubMed PMID: 40830141; PubMed Central PMCID: PMC12365225.
  4. Watson A, Patil T, Schenk E, Camidge D. Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review. Current Problems in Cancer: Case Reports. 2025/03; 17:100348.
  5. Phillips WJ, Watson AS, Camidge DR. The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments. J Thorac Oncol. 2025 May;20(5):589-596. doi: 10.1016/j.jtho.2024.12.003. Epub 2024 Dec 4. PubMed PMID: 39643116.
  6. Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2025 Jan;199:108040. doi: 10.1016/j.lungcan.2024.108040. Epub 2024 Nov 25. PubMed PMID: 39615411; PubMed Central PMCID: PMC11787869.
  7. Watson AS, Krause HB, Elliott A, Farrell A, Liu SV, Ma PC, VanderWalde A, Sledge GW, Spetzler D, Schenk EL, Camidge DR. Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2024 Dec;25(8):712-722.e1. doi: 10.1016/j.cllc.2024.09.001. Epub 2024 Sep 12. PubMed PMID: 39384504.
  8. Watson AS, Goutam S, Stukalin I, Ewanchuk BW, Sander M, Meyers DE, Pabani A, Cheung WY, Heng DYC, Cheng T, Monzon JG, Navani V. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy. JAMA Netw Open. 2022 Dec 1;5(12):e2245596. doi: 10.1001/jamanetworkopen.2022.45596. PubMed PMID: 36480204; PubMed Central PMCID: PMC9856439
© Department of Oncology

Contact Us

DEPARTMENT OF ONCOLOGY

ARTHUR J.E. CHILD COMPREHENSIVE CANCER CENTRE

3395 HOSPITAL DRIVE. N.W. CALGARY AB CANADA T2N 4N1

Links